'Pay for Delay' | GenomeWeb

'Pay for Delay'

The EU's competition commissioner issued the final report from investigating the delays in generic drugs coming to the market, reports the Wall Street Journal's Health Blog. The report acknowledged that innovation difficulties and regulation affect the time it takes to get a generic to market and suggested that the EU have a single patent and litigation system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.